, Lancet Lond Engl, vol.389, issue.16, pp.32126-32128, 2017.
Peyrin-Biroulet L. Crohn's disease, Lancet Lond Engl, vol.389, issue.16, pp.31711-31712, 2017. ,
,
Treat to target: a proposed new paradigm for the management of Crohnés disease, Clin Gastroenterol Hepatol, vol.13, issue.6, pp.1042-50, 2015. ,
, Selecting Therapeutic Targets in Inflammatory Bowel Disease
URL : https://hal.archives-ouvertes.fr/hal-01191653
, Determining Therapeutic Goals for Treat-to-Target, Am J Gastroenterol, vol.110, issue.9, pp.1324-1362, 2015.
,
, European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal
, Inflammatory Bowel Disease, vol.12, pp.17-31, 2018.
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped, Gastroenterology, vol.142, issue.1, pp.63-70, 2012. ,
Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study, Am J Gastroenterol, vol.112, issue.1, pp.120-151, 2017. ,
,
, Vedolizumab as induction and maintenance therapy for Crohn's disease, N Engl J Med, vol.369, issue.8, pp.711-732, 2013.
,
Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, vol.369, issue.8, pp.699-710, 2013. ,
, Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed, Gastroenterology, vol.147, issue.3, pp.618-627, 2014.
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry, Aliment Pharmacol Ther, vol.48, issue.8, pp.839-51, 2018. ,
,
, Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease, J Gastroenterol, vol.53, issue.9, 2018.
,
, Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease
,
, a prospective multi-centre cohort study, Aliment Pharmacol Ther, vol.50, issue.1, pp.40-53, 2019.
Stopping Biologics in IBD-What Is the Evidence?, Inflamm Bowel Dis, vol.24, issue.4, pp.725-756, 2018. ,
Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis, J Crohns Colitis, vol.12, issue.2, pp.245-57, 2018. ,
,
, Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.14, issue.11, 2016.
Oneyear effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicenter cohort study, press. 19. Gisbert JP, vol.111, pp.632-679, 2017. ,
,
, Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine, Lancet Lond Engl, vol.347, issue.8996, pp.215-224, 1996.
Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term, Pharmacol Ther, vol.42, issue.4, pp.391-405, 2015. ,
Longterm outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort, Gut, vol.58, issue.4, pp.492-500, 2009. ,
,
, Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial, Lancet Lond Engl, vol.390, issue.17, pp.32641-32648, 2018.
,
, Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis, Aliment Pharmacol Ther, vol.43, issue.8, pp.910-933, 2016.
,
, Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.7, issue.1, pp.80-85, 2009.